



Short version of press release from Emotra AB
Gothenburg September 18, 2013

Emotra publishes new website in Swedish and English

- *In clinical studies a strong relationship between hyporeactivity and risk for suicide has been demonstrated*
- *Emotra has developed, EDOR, ElektroDermal Orientation Reactivity, and objective and quantitative psychophysiological test for the measurement of hyporeactivity*
- *Evaluation of suicide risk is the most challenging problem for the psychiatric care to solve*

Emotra is at present in a very dynamic phase and its activities involve an increasing number of clinical centers. A number of clinical evaluations are under preparation. Contracts have been signed with leading European clinical teams. There are ongoing discussions with others who want to be involved in evaluation of the technique at an early stage.

The increased international exposition and engagement has led the company to decide to publish a new website. www.emotra.se, in Swedish as well as in English. It is justified to expect the new website to significantly simplify for researchers, psychiatrists, psychologists and investors from other countries, to find information about the company and the company's method, business and plans for the future.

When the support for EDOR is strong enough, from leading clinical teams participating in the evaluation, the method will be launched in Europe. This can certainly happen before all clinical teams have completed their studies. CE-marking of the product will be finalized during the next six months. All work in Emotra will be performed in a small organization and at a low cost level.

The psychiatric care has relevant preventive actions and resources to use when risk for suicide has been identified. Unfortunately there are today no accurate methods for the identification of risk patients, with the use of EDOR this difficult diagnostic problem can be solved. The test does not take more than 15 minutes. With necessary preparations, the total time is 30 minutes. The introduction of EDOR as a clinical routine procedure has the potential to substantially reduce the number of suicides and suicide attempts in the world.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se